Robert Orr, U.S. Food and Drug Administration. fda.gov. October 25, 2023.
The 2023 FDA presentation repeats 75F40120C00176 as an FDA/OMHHE collaboration studying COVID-19 illness in diverse populations. It provides a later official account of the same funding relationship described in 2022, rather than a new independent study or award. Nolan’s connection comes from the separate MaxFuse acknowledgement; no classified UAP access is reported.
◧ Partial root native PDF text and selected layout review
Robert Orr, U.S. Food and Drug Administration. fda.gov. December 6, 2022.
Robert Orr’s FDA presentation publicly describes a 2017 modification of contract HHSF223201610018C and links 75F40120C00176 to a collaboration studying COVID-19 illness in diverse populations. These identifiers match contracts acknowledged for Nolan in MaxFuse. The slides document agency statements about public research funding; they do not name Nolan or establish secret invitations or UAP access.
◧ Partial root native PDF text and selected layout review
A curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach